TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Sponsor: Rigel Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT06161974 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06161974 Rescue Dossier →